Details for Patent: 8,122,917

✉ Email this page to a colleague

Which drugs does patent 8,122,917 protect, and when does it expire?

Patent 8,122,917 protects VARITHENA and is included in one NDA.

This patent has twenty-three patent family members in eighteen countries.

Summary for Patent: 8,122,917

Title:	Apparatus and method for dispensing foam
Abstract:	A foam transfer device is described, for use with aerosol canister apparatus for producing a sclerosant foam for the treatment of, inter alia, varicose veins. The device enables diversion of an initial quantity of below-specification foam from the canister to waste, e.g. to an integral waste chamber, before dispensing a further quantity of foam for use in treatment. The switching of the flow from the waste chamber to a different outlet for use is accomplished without interrupting the flow from the aerosol canister since this would cause the foam to drop below specification again. The waste chamber may be transparent so that the foam entering it can be observed and a decision made by a user when to stop diverting foam to waste. Alternatively, the foam may be diverted automatically e.g. when a set time has elapsed or a set volume of foam dispensed. The foam for use is normally dispensed into a syringe for subsequent injection into a varicose vein of a patient.
Inventor(s):	Harman; Anthony David (Oxon, GB), Wright; David Dakin Iowerth (High Waycombe, GB), Mijers; Jam Wilem Marinus (Haarlem, NL), Kay; Stuart Brian William (Cambridge, GB), Hurlstone; Christopher John (Cambridge, GB), Dixon; Julina Richard (Cambridge, GB), Pocock; Andrew Gordon (Cambridge, GB), Hogan; Brendan (Co Galway, IE)
Assignee:	BTG International Limited (London, GB)
Application Number:	12/923,209
Patent Claim Types: see list of patent claims	Device;

Drugs Protected by US Patent 8,122,917

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Provensis	VARITHENA	polidocanol	SOLUTION;INTRAVENOUS	205098-001	Nov 25, 2013		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,122,917

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0321210.7	Sep 10, 2003

International Family Members for US Patent 8,122,917

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	486023	⤷ Sign Up
Australia	2004270475	⤷ Sign Up
Brazil	PI0414281	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.